Paolini John F. 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Nov 4, 2025
Insider Transaction Report
Form 4
Paolini John F.
CHIEF MEDICAL OFFICER
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-10-31$3.80/sh+36,542$138,860→ 97,866 total - Exercise/Conversion
Class A Ordinary Share
2025-10-31$8.83/sh+46,000$406,180→ 143,866 total - Exercise/Conversion
Share Option
2025-10-31−36,542→ 0 totalExercise: $3.80Exp: 2027-06-28→ Class A Ordinary Share (36,542 underlying) - Sale
Class A Ordinary Share
2025-10-31$37.14/sh−82,542$3,065,610→ 61,324 total - Exercise/Conversion
Share Option
2025-10-31−46,000→ 0 totalExercise: $8.83Exp: 2029-09-16→ Class A Ordinary Share (46,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.80 and $37.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.